Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$73.43
-$0.55(-1.77%)
At close: 4:00 PM EST
$73.43
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$23.65 - $77.00
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.15M
Market Cap
$6.13B
Enterprise Value$5.30B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$7.58M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 07, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume933,760
30 Day Avg. Volume1,150,387
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.05K
Enterprise Value/Gross Profit-157.33
Enterprise Value/Ebitda-28.75
Forecast
1Y Price Target
$91.55Price Target Upside24.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.74
Revenue Forecast (FY)$11.76M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and sizable equity provide durable financial flexibility to fund R&D and potential commercialization windows without immediate refinancing. This cushion lengthens runway, supports strategic option value, and reduces near-term solvency risk even with ongoing operating losses.
Experienced Financial LeadershipSecuring a CFO with deep biotech finance experience strengthens capital planning, milestone-based financing execution, and readiness for commercialization accounting. Experienced treasury and financing execution are durable advantages when navigating large R&D spend and complex funding rounds.
Shareholder Governance SupportBroad shareholder approval of directors, auditor ratification, and governance practices signals stable oversight and investor alignment. Strong governance continuity supports disciplined decision-making through clinical and commercial inflection points, reducing execution risk over the medium term.
Bears Say
High Cash BurnSustained and increasing cash outflows create a persistent funding overhang that forces frequent capital raises or strategic partnerships. Over 2–6 months this structural burn rate pressures runway, risks dilution, and constrains the ability to scale commercial activities without new financing.
Negative Gross Profit & Large LossesNegative gross margin and deep, widening operating losses indicate the cost base far exceeds current revenue. Until product approvals or recurring sales materialize, profitability is structurally distant, making long-term self-sustainability dependent on successful clinical and commercial execution.
No Commercial Revenue StreamBeing clinical-stage with no recurring sales means the business depends on equity and other financing to fund operations. This structural reliance raises dilution and execution risk, and ties strategic flexibility to capital markets and milestone-based funding over the medium term.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $23.65 and its highest was $77.00 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $6.13B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 19 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on May 08, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.154.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.66.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,202,480 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went up 0.636%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.55 (24.67% Upside)
$91.55 (24.67% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 20.8%
Last 30 Days ▲ 20.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.45%
12-Months-Change
Fundamentals
Return on Equity
-23.33%
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CGON Stock 12 Month Forecast
Average Price Target
$91.55
▲(24.67% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.35% Insiders
28.66% Mutual Funds
0.11% Other Institutional Investors
44.69% Public Companies and
Individual Investors